KY-226
Modify Date: 2024-09-27 19:18:07
KY-226 structure
|
Common Name | KY-226 | ||
|---|---|---|---|---|
| CAS Number | 1621673-53-7 | Molecular Weight | 481.669 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H31NO3S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of KY-226KY-226 (KY226) is a potent, allosteric, orally active inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 uM (human PTP1B), does not exhibit PPARγ agonist activity; shows no effects on adipocyte differentiation in rodent preadipocytes at 10 uM, bot not the PPARγ agonist pioglitazone; increases the phosphorylated insulin receptor (pIR) produced by insulin in human hepatoma-derived cells (HepG2) at 0.310 uM, significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain in db/db mice, exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling. |
| Name | KY-226 |
|---|
| Description | KY-226 (KY226) is a potent, allosteric, orally active inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 uM (human PTP1B), does not exhibit PPARγ agonist activity; shows no effects on adipocyte differentiation in rodent preadipocytes at 10 uM, bot not the PPARγ agonist pioglitazone; increases the phosphorylated insulin receptor (pIR) produced by insulin in human hepatoma-derived cells (HepG2) at 0.310 uM, significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain in db/db mice, exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling. |
|---|---|
| References | References 1. Ito Y, et al. J Pharmacol Sci. 2018 May;137(1):38-46. 2. Sun M, et al. Brain Res. 2018 Sep 1;1694:1-12. View Related Products by Target Protein Phosphatase/PTP |
| Molecular Formula | C27H31NO3S2 |
|---|---|
| Molecular Weight | 481.669 |